BNC says nano approach can aid drug-target research

- Last updated on GMT

Related tags: Nanotechnology

Bio Nano Consulting (BNC) launches new fluorescent tag-free technique that it says can help evaluate protein stability and ligand binding in drug discovery.

The approach uses microfluidics and microcapillaries techniques to measure the intrinsic fluorescence of nano-scale quantities of protein, eliminating both the need for additional labelling or to use large quantities of the usually precious compound under analysis.

BNC’s research partners worked with scientists at the London Centre for Nanotechnology to determine the affinity of rapamycyin to the cellular immunophilin FKBP12 to gain a better insight into target-drug interaction.

CEO David Sarphie said: “We are delighted to be able to offer access to this innovative technique developed by scientific researchers at UCL and LCN to our clients.

Sarphie added that: “[the new] method has vast implications and uses in high throughput, low cost platforms for drug discovery, protein engineering and protein formulation applications in the pharmaceutical industry.”

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars